

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1 to 5. (canceled)

Claim 6. (currently amended) An aqueous ophthalmic solution comprising ~~0.001 to 0.01~~ 0.005% (W/V) latanoprost as an active ingredient, wherein the latanoprost is stabilized to be stored at room temperature by adding  $\epsilon$ -aminocaproic acid to the solution.

Claim 7. (canceled)

Claim 8. (previously presented) The ophthalmic solution as claimed in claim 6, wherein the  $\epsilon$ -aminocaproic acid is in a concentration of 0.1 to 2% (W/V).

Claim 9. (canceled)

Claim 10. (previously presented) The ophthalmic solution as claimed in claim 6, wherein the  $\epsilon$ -aminocaproic acid is in a concentration of 1% (W/V).

Claim 11. (canceled)

Claim 12. (currently amended) An aqueous ophthalmic solution comprising ~~0.001 to 0.01~~ 0.005% (W/V) latanoprost as an active ingredient, wherein the latanoprost is stabilized to be stored at room temperature by adjusting the pH of the solution to 5.0 to 6.25 and adding  $\epsilon$ -aminocaproic acid to the solution.

Claim 13. (canceled)

Claim 14. (previously presented) The ophthalmic solution as claimed in claim 12, wherein the  $\epsilon$ -aminocaproic acid is in a concentration of 0.1 to 2% (W/V).

Claim 15. (canceled)

Claim 16. (previously presented) The ophthalmic solution as claimed in claim 12, wherein the  $\epsilon$ -aminocaproic acid is in a concentration of 1% (W/V).

Claim 17. (canceled)